期刊文献+

E1B缺失腺病毒H101的研究进展 被引量:1

Review of the empirical study and clinical research of E1B-deleted virus
全文增补中
导出
摘要 E1B缺失腺病毒H101是采用基因重组技术对人5型腺病毒进行基因重组得到的一种溶瘤腺病毒,它主要是删除了人5型腺病毒的E1B-55×10~3和E3区19×10~3基因片段,具有在肿瘤细胞中特异性复制而最终导致溶瘤的特性。 H101 is a genetically modified Ad5 based,E1B-deleted and replication competent virus (oncolytic virus),in which the region of 2502 bp to 3327 bp was deleted and there was a C to T transition at position 2025 and it allow selective replication in and lysis tumor cells.
出处 《肿瘤研究与临床》 CAS 2007年第6期429-432,共4页 Cancer Research and Clinic
基金 国家自然基金项目(30400536) 国家重大基础研究项目(No.2004CB518804)
关键词 腺病毒E1B蛋白质类 基因治疗 研究 E1B gene-deleted adenovirus Gene therapy Research
  • 相关文献

参考文献9

二级参考文献73

  • 1夏忠军,常建华,张力,姜文奇,管忠震,刘基巍,张阳,胡晓桦,吴国华,王华庆,陈正常,陈建超,周清华,陆建伟,樊青霞,黄建瑾,郑晓.基因工程腺病毒(H101)瘤内注射联合化疗治疗头颈部及食管鳞癌的Ⅲ期临床研究[J].癌症,2004,23(12):1666-1670. 被引量:50
  • 2蔡鹏,刘叙仪,韩复生,王萍.耐顺铂人肺腺癌细胞系A_(549)DDP的建立及耐药机制[J].中国肿瘤临床,1995,22(8):582-587. 被引量:29
  • 3沈惠麒 赵利英.组织中谷胱甘肽的荧光测定法[J].中华劳动卫生职业病杂志,1988,6:103-108.
  • 4[1]Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells[J]. Science,1996,274(5286):373- 376.
  • 5[2]Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer[J]. J Clin Oncol, 2001,19(2):289- 298.
  • 6[3]Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer[J]. Nat Med,2000,6(8):879- 885.
  • 7[4]Ganly I, Eckhardt SG, Rodriguez GI, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer[J]. Clin Cancer Res,2000,6(3):798- 806.
  • 8[5]Habib NA, Sarraf CE, Mitry RR, et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors[J]. Hum Gene Ther,2001,12(3): 219- 226.
  • 9[6]Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial[J]. Gene Ther, 2001, 8(4): 308- 315.
  • 10[7]Heise C,Wukkuans AM,Xue S, et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy[J]. Cancer Res, 1999, 59: 2623- 2628.

共引文献87

同被引文献9

  • 1WANG Y, HU F. Clinical trials with oncolytic adenovirus in China [ J ]. Current Drug Targets, 2007,7 ( 2 ) :659-670.
  • 2VORBURGER S A, HUNT K K. Adenoviral gene therapy[J]. The Oncologist , 2002, 7:46-59.
  • 3BISCHOFF J R, KIRN D H, WILLIAMS A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells[J]. Sci, 1996, 274 (5286):373-376.
  • 4BIEDERER C, RIES S, BRANDTS C H, et al. Replication-selective viruses for cancer therapy [ J ]. J Mol Med, 2002, 80 (3) : 163-175.
  • 5MELCHER A, MURPHY S, VILE R. Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors[J]. Hum Gene Ther, 1999, 10 (9) :1431-1442.
  • 6MELCHER A, TODRYK S, HARDWICK N, et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression[ J]. Nat Med, 1998, 4 (5) :581-587.
  • 7VILE R G, HART I R. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA[J]. Cancer Res, 1993, 53 (17) :3860-3864.
  • 8钱其军,吴孟超,王晋,刘新垣,车小燕,岑信棠.恶性肿瘤治疗的新策略——基因-病毒治疗[J].肿瘤学杂志,2001,7(4):193-195. 被引量:2
  • 9张波,邹卫国,吴国豪,靳大勇,许德华,郑仲承,吴肇汉,刘新垣.人内皮抑素转基因治疗B16黑色素瘤的实验研究[J].中华肿瘤杂志,2002,24(5):451-454. 被引量:8

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部